Published in Proc Natl Acad Sci U S A on March 25, 2013
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol (2014) 3.68
The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet (2014) 3.17
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Integrative annotation of variants from 1092 humans: application to cancer genomics. Science (2013) 2.98
Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet (2014) 2.86
Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer (2013) 2.69
The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol (2014) 2.63
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell (2014) 2.57
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol (2014) 2.42
Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science (2015) 2.37
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst (2014) 2.29
A nondegenerate code of deleterious variants in Mendelian loci contributes to complex disease risk. Cell (2013) 2.28
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell (2016) 2.27
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer (2014) 2.10
EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov (2014) 1.99
Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science (2015) 1.91
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res (2014) 1.86
Proteostatic control of telomerase function through TRiC-mediated folding of TCAB1. Cell (2014) 1.82
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci U S A (2013) 1.82
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab (2013) 1.76
Neuroblastoma and MYCN. Cold Spring Harb Perspect Med (2013) 1.75
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab (2014) 1.71
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol (2013) 1.63
Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet (2014) 1.63
BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol (2015) 1.62
Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements. Genes Dev (2013) 1.61
Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle (2013) 1.52
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab (2014) 1.52
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist (2016) 1.51
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol (2014) 1.49
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget (2014) 1.40
TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res (2013) 1.39
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38
FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer. Genome Biol (2014) 1.36
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife (2015) 1.28
Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev (2014) 1.22
TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol (2014) 1.21
Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat Cell Biol (2015) 1.18
The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia (2014) 1.15
TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer (2014) 1.14
Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes Cancer (2013) 1.12
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol (2015) 1.11
Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer (2014) 1.10
Role of non-coding sequence variants in cancer. Nat Rev Genet (2016) 1.10
Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma. J Hepatol (2014) 1.09
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet (2014) 1.09
Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch (2014) 1.09
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res (2014) 1.08
Molecular mechanisms of ETS transcription factor-mediated tumorigenesis. Crit Rev Biochem Mol Biol (2013) 1.08
Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol (2015) 1.06
Induced Pluripotent Stem Cells Meet Genome Editing. Cell Stem Cell (2016) 1.06
TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet (2015) 1.05
Role of Telomeres and Telomerase in Aging and Cancer. Cancer Discov (2016) 1.03
Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget (2015) 1.03
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res (2014) 1.02
A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression. Genome Biol (2015) 1.02
TERT promoter mutations in thyroid cancer. Endocr Relat Cancer (2016) 1.01
Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol (2015) 1.01
Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev (2015) 1.01
IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget (2015) 0.99
Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head Neck (2014) 0.98
Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A (2015) 0.98
Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol (2014) 0.97
Telomere maintenance and the etiology of adult glioma. Neuro Oncol (2015) 0.97
TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget (2015) 0.96
Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer (2015) 0.96
Recurrent epimutations activate gene body promoters in primary glioblastoma. Genome Res (2014) 0.95
TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. Oncotarget (2014) 0.95
Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Br J Cancer (2014) 0.95
TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One (2013) 0.95
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol (2015) 0.94
TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget (2014) 0.94
Telomere length and risk of glioma. Cancer Epidemiol (2013) 0.94
Inhibition of telomerase recruitment and cancer cell death. J Biol Chem (2013) 0.94
The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer (2014) 0.94
Stop pulling my strings - what telomeres taught us about the DNA damage response. Nat Rev Mol Cell Biol (2016) 0.93
Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol (2015) 0.93
Protein residues that control the reaction trajectory in S-adenosylmethionine radical enzymes: mutagenesis of asparagine 153 and aspartate 155 in Escherichia coli biotin synthase. Biochemistry (2009) 0.93
TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma. Oncotarget (2014) 0.93
BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget (2016) 0.93
Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. Oncotarget (2014) 0.93
Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol (2015) 0.93
TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. Oncotarget (2015) 0.93
Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol (2015) 0.92
TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas. PLoS One (2014) 0.91
Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PLoS One (2016) 0.90
Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Arch (2014) 0.90
Understanding TERT Promoter Mutations: A Common Path to Immortality. Mol Cancer Res (2016) 0.90
Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med (2015) 0.90
The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer. Oncotarget (2015) 0.89
Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol (2015) 0.89
Clonal architectures and driver mutations in metastatic melanomas. PLoS One (2014) 0.89
Signatures of accelerated somatic evolution in gene promoters in multiple cancer types. Nucleic Acids Res (2015) 0.89
OncoCis: annotation of cis-regulatory mutations in cancer. Genome Biol (2014) 0.89
The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform. JAMA Oncol (2016) 0.88
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
A survey of telomerase activity in human cancer. Eur J Cancer (1997) 10.84
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol (2009) 9.84
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol (2012) 8.16
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
TERT promoter mutations in familial and sporadic melanoma. Science (2013) 7.82
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Retrospective birth dating of cells in humans. Cell (2005) 5.60
Telomeres and aging. Physiol Rev (2008) 4.79
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet (2010) 4.26
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012) 3.88
Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (2011) 3.49
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
The origins of medulloblastoma subtypes. Annu Rev Pathol (2008) 3.36
Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity (1996) 2.71
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem (1999) 2.34
Telomere and telomerase in stem cells. Br J Cancer (2007) 2.09
Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation (2002) 1.99
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol (2010) 1.98
Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol (1997) 1.95
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget (2010) 1.88
OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res (2009) 1.77
Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res (2002) 1.64
Liposarcoma: molecular genetics and therapeutics. Sarcoma (2010) 1.55
Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res (2006) 1.44
Telomere reduction in human liver tissues with age and chronic inflammation. Exp Cell Res (2000) 1.42
Telomerase is controlled by protein kinase Calpha in human breast cancer cells. J Biol Chem (1998) 1.38
Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol (2010) 1.33
Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol (2011) 1.32
Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol (1996) 1.30
HPV E6 protein interacts physically and functionally with the cellular telomerase complex. Proc Natl Acad Sci U S A (2009) 1.21
Oligodendrogliomas: molecular biology and treatment. Oncologist (2009) 1.21
Telomerase activity and hTERT mRNA expression in glial tumors. Int J Oncol (2006) 1.18
PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest (2012) 1.16
The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. Oncogene (2008) 1.10
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Cancer genome landscapes. Science (2013) 25.33
Cancer genes and the pathways they control. Nat Med (2004) 24.22
International network of cancer genome projects. Nature (2010) 20.35
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature (2012) 11.68
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26